|
Coronary Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
PTEN inhibition attenuates endothelial cell apoptosis in coronary heart disease via modulating the AMPK-CREB-Mfn2-mitophagy signaling pathway.
|
31654396 |
2020 |
|
Coronary heart disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
PTEN inhibition attenuates endothelial cell apoptosis in coronary heart disease via modulating the AMPK-CREB-Mfn2-mitophagy signaling pathway.
|
31654396 |
2020 |
|
Fibrosis, Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings indicate that MFN2 is critical in regulating apoptosis and liver fibrosis in HSCs, which might be a useful therapeutic target to treat liver fibrosis.
|
31802713 |
2020 |
|
Endothelial dysfunction
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Maternal serum Mfn2 is higher in patients with preeclampsia suggesting that Mfn2 increases in the maternal system as a stress response against hypoxia and endothelial dysfunction.What do the results of this study add?
|
30614327 |
2020 |
|
Coronary Artery Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
PTEN inhibition attenuates endothelial cell apoptosis in coronary heart disease via modulating the AMPK-CREB-Mfn2-mitophagy signaling pathway.
|
31654396 |
2020 |
|
Arteriosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Aberrant MFN2 transcription facilitates homocysteine-induced VSMCs proliferation via the increased binding of c-Myc to DNMT1 in atherosclerosis.
|
31104361 |
2019 |
|
Atherosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Aberrant MFN2 transcription facilitates homocysteine-induced VSMCs proliferation via the increased binding of c-Myc to DNMT1 in atherosclerosis.
|
31104361 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry was used to investigate MFN2 expression in 117 bladder cancer specimens.
|
31402945 |
2019 |
|
Bladder Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry was used to investigate MFN2 expression in 117 bladder cancer specimens.
|
31402945 |
2019 |
|
Brain Ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, a translocation of the Mfn2 protein to the cytoplasm was documented immediately after global brain ischemia in the neurons of the cerebral cortex by laser scanning confocal microscopy.
|
31017259 |
2019 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using human retinal endothelial cells, manipulated for Mfn2, we investigated the role of fusion in mitochondrial structural and functional damage in diabetes.
|
30922813 |
2019 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
Using human retinal endothelial cells, manipulated for Mfn2, we investigated the role of fusion in mitochondrial structural and functional damage in diabetes.
|
30922813 |
2019 |
|
Fibromyalgia
|
0.010 |
Biomarker
|
disease |
BEFREE |
First, we underlined that RIM rats are a good model for studying the pathophysiology of FMS and moreover, we found that PGC-1α, Mfn2, and CoQ10 are involved in FMS.
|
30754674 |
2019 |
|
Hepatic Encephalopathy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The drp1 and mfn2 genes were up-regulated, then, the Opa1 exhibited no significant change in the ACC of HE mice.
|
30290401 |
2019 |
|
HIV Infections
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Here, we show that upon HIV infection, macrophages increase the expression of BCL2, BCLXL, TREM1, mitofusin 1 (MFN1), and MFN2 and the translocation of BCL2L11 (BIM) to the mitochondria and decrease the expression of BCL2-associated agonist of cell death (BAD) and BAX while maintaining a 95% survival rate over 28 days.
|
31719184 |
2019 |
|
Lipomatosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
MFN2-associated lipomatosis: Clinical spectrum and impact on adipose tissue.
|
30158064 |
2019 |
|
Liver diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Ablation of Mfn2 in liver reveals that disruption of ER-mitochondrial PS transfer is a new mechanism involved in the development of liver disease.
|
31051106 |
2019 |
|
Chronic Obstructive Airway Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of the hyperplasia suppressor gene inactivates airway fibroblasts obtained from a rat model of chronic obstructive pulmonary disease by inhibiting the Wnt signaling pathway.
|
31322244 |
2019 |
|
Retinal Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Thus, regulating Mfn2 and its epigenetic modifications by molecular/pharmacological means will protect mitochondrial homeostasis in diabetes, and could attenuate the development of retinopathy in diabetic patients.
|
30922813 |
2019 |
|
Renal fibrosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In addition, mitophagy in macrophages involves PINK1-mediated phosphorylation of downstream MFN2, MFN2-facilitated recruitment of Parkin to damaged mitochondria, and macrophage-specific deletion of Mfn2 aggravates kidney fibrosis.
|
31639106 |
2019 |
|
Dissection of aorta
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Single Nucleotide Polymorphisms (SNPs) Genotyping Reveals that Mfn2 Polymorphisms are Associated with Thoracic Aortic Dissection in Han Chinese Population.
|
30940795 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Finally, muscle miR-34a expression and mitofusin 2 (Mfn2) protein levels correlated with hallmarks of NAFLD and disease progression.
|
31139863 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
HDAC2 knockout mice demonstrate reduced injury in the middle cerebral artery occlusion with reperfusion (MCAO/R) model of cerebral ischemia demonstrating enhanced neuronal survival, minimized loss of Endo-B1, and normalized expression of Mfn2.
|
30028551 |
2019 |
|
infertility tubal factor
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cases had TFI, and controls had no TFI (ie normal findings during HSG or laparoscopy).
|
30629310 |
2019 |
|
Lipoatrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
MFN2-related MSL is a novel mitochondrial lipodystrophic syndrome involving both lipomatous masses and lipoatrophy.
|
30158064 |
2019 |